|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
Novartis_assets
|
|
gptkbp:campaigns
|
collaborations with health organizations
|
|
gptkbp:campusFacilities
|
gptkb:University_of_Mainz
|
|
gptkbp:CEO
|
Uğur Şahin
|
|
gptkbp:challenges
|
cold chain logistics.
|
|
gptkbp:clinicalTrials
|
over 40,000
multiple countries
Phase 3
various cancer therapies
|
|
gptkbp:collaborations
|
gptkb:CureVac
gptkb:Moderna
international research teams
|
|
gptkbp:commissioningDate
|
December 2020
|
|
gptkbp:community_engagement
|
public health initiatives
|
|
gptkbp:community_outreach
|
positive feedback
|
|
gptkbp:diseaseResistance
|
95% against COVID-19
|
|
gptkbp:distribution
|
various logistics companies
|
|
gptkbp:dosageForm
|
over 1 billion
|
|
gptkbp:employeeCount
|
over 1,000
|
|
gptkbp:founded
|
2008
|
|
gptkbp:founder
|
Uğur Şahin
|
|
gptkbp:funding
|
various institutions
|
|
gptkbp:headquarters
|
gptkb:Mainz,_Germany
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
BNTX
|
|
gptkbp:impact
|
reduced hospitalization rates
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:innovation
|
first mRNA vaccine approved
|
|
gptkbp:investmentFocus
|
$300 million from the German government
|
|
gptkbp:market
|
approximately $20 billion
|
|
gptkbp:network
|
gptkb:Pfizer
|
|
gptkbp:notable_player
|
EMA
global
lipid nanoparticles
-70 degrees Celsius
|
|
gptkbp:notableEvent
|
gptkb:COVID-19_vaccine
|
|
gptkbp:partnerships
|
gptkb:GSK
gptkb:Pfizer
Fosun Pharma
|
|
gptkbp:patentDescription
|
multiple patents filed
|
|
gptkbp:regulatoryCompliance
|
gptkb:FDA
|
|
gptkbp:research
|
ongoing
conducted post-approval
|
|
gptkbp:research_focus
|
mRNA technology
|
|
gptkbp:safety
|
monitored_by_CDC
|
|
gptkbp:scientificName
|
Comirnaty
|
|
gptkbp:stockExchange
|
gptkb:BNTX
|
|
gptkbp:supplyChain
|
global_logistics_management
|
|
gptkbp:technology
|
continuous improvements
|
|
gptkbp:triggerType
|
gptkb:mRNA
|
|
gptkbp:type
|
public company
|
|
gptkbp:variant
|
adaptation in development
|
|
gptkbp:website
|
www.biontech.de
|